Dr. Patrick M. Connors, M.D.
Internal Medicine (Internal Medicine Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
NY license 209207
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 5 companies. The companies reported $969,536 in research payments for these studies, mostly to the institutions running them.
- A phase 12 randomized doubleblind trial of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in adults 18 years of age and older
Pfizer Inc. - A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
ModernaTX, Inc. · Completed · NCT05975099 - A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06230523 - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT06603571 - A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant…
Novavax Inc - A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Recruiting · NCT06143956 - A phase 3 placebocontrolled doubleblinded randomized study to evaluate the efficacy safety and tolerability of a clostridioides difficile vaccine in adults 65 years of age and older
Pfizer Inc. - A phase 3 study to evaluate the safety tolerability and immunogenicity of a respiratory syncytial virus rsv prefusion f subunit vaccine in adults 60 years of age and older
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.